Role of Platelet Rich Plasma in Enhancing Graft Take in Chronic Venous Ulcers

NCT ID: NCT03526913

Last Updated: 2018-05-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-02-01
• Study Completion Date: 2018-02-01

Brief Summary

Chronic venous ulcers are considered a problem with a big morbidity impact on both the health facilities and patients, skin-grafting have shown not so perfect outcomes with such ulcers. In this study, the investigators compare combining autologous platelet rich plasma treatments with partial skin grafting in chronic ulcers, the results were compared to using only partial skin grafting, and among various types of chronic resistant ulcers.

Detailed Description

Fourteen patients had bilateral lower limb ulcers, and 6 of them had single large ulcers as follows; Fourteen patients with chronic venous ulcers (12 of which had bilateral ulcers, 2 had single large ulcers) Four patients, each with a single chronic post-traumatic ulcer Two patients with bilateral chronic lymphatic ulcers.

After detailed history, physical examination and investigations (such as duplex),

• Each patient with bilateral ulcers included in the study (14 patients) received treatment A on one ulcer and treatment B on the other ulcer.
• In case of patients with single large ulcers (6 patients), treatment A was done on one half of the ulcer and treatment B on the other half of the ulcer (done in ulcers with an area greater than 10 x 10 cms).
• Treatment A included pre-operative intra-lesional PRP injections in 1-week intervals for 3 times, followed by intra-operative intra-lesional injection of PRP prior to meshed graft placement. PRP was injected into the ulcer bed and ulcer edges using a sterile syringe.

Treatment B included only placement of meshed graft, with no PRP treatment.

• Pre-operative preparation: Ulcers were prepared by proper dressings and followed up until acquiring a clean bed. Debridement was done as needed to obtain clean base ready for graft placement.
• PRP preparation:

• 10 ml of blood was drawn from each patient intra operatively (autologous PRP).
• Blood was collected in sterile tubes, Anticoagulant Citrate Dextrose (ACD) was used for anticoagulation, which is the same substance used to preserve viable platelets in blood banks for platelet transfer.
• Tubes were centrifuged in Beckman Allerga X-12 centrifuge for 20 mins, 3000 rpm.
• Each 10 ml of blood yielded an average of 3-4 ml of PRP. Calcium gluconate was added in a ratio of 1:10 to PRP. Post-operative assessment was carried out by follow up clinical examination, photography and weekly biopsy samples.

Conditions

Chronic Venous Hypertension With Ulcer and Inflammation; Chronic Ulcer of Leg or Foot

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: FACTORIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

PRP + STSG

autologous PRP treatments every week prior to graft placement (STSG)

Group Type: EXPERIMENTAL

PRP

Intervention Type: PROCEDURE

PRP: autologous platelet-rich plasma

STSG

Intervention Type: PROCEDURE

skin graft: Split Thickness Skin Grafting (STSG)

STSG Split Thickness Skin Graft

skin graft (STSG) (intervention)

Group Type: ACTIVE_COMPARATOR

STSG

Intervention Type: PROCEDURE

skin graft: Split Thickness Skin Grafting (STSG)

Interventions

PRP

PRP: autologous platelet-rich plasma

Intervention Type: PROCEDURE

STSG

skin graft: Split Thickness Skin Grafting (STSG)

Intervention Type: PROCEDURE

Other Intervention Names

platelet rich plasma; split thickness skin graft

Eligibility Criteria

Inclusion Criteria

• Patients with chronic ulcers for at least 6 months.
• Age ≧ 12 years.

Exclusion Criteria

• Patients younger than 12 years of age.
• Patients with diabetes or other diseases affecting tissue healing.
• Patients with current ongoing pathologies in arterial or venous systems.
• Patients with malignant ulcers.
• Patients on corticosteroids or other drugs affecting tissue healing.
• Patients with unrealistic expectations.

• Minimum Eligible Age: 12 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Menoufia University

OTHER

Sponsor Role: collaborator

Noha Mohsen Omar

OTHER

Sponsor Role: lead

Responsible Party

Noha Mohsen Omar

Principal Investigator, MBBCH Cairo University

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Sherif M. Elkashty, PHD

Role: PRINCIPAL_INVESTIGATOR

Menoufia University

References

Fonder MA, Lazarus GS, Cowan DA, Aronson-Cook B, Kohli AR, Mamelak AJ. Treating the chronic wound: A practical approach to the care of nonhealing wounds and wound care dressings. J Am Acad Dermatol. 2008 Feb;58(2):185-206. doi: 10.1016/j.jaad.2007.08.048.

Reference Type: BACKGROUND

PMID: 18222318 (View on PubMed)

Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol. 2008 Jan 15;75(2):346-59. doi: 10.1016/j.bcp.2007.07.004. Epub 2007 Jul 7.

Reference Type: BACKGROUND

PMID: 17678629 (View on PubMed)

Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev. 2003 Jul;83(3):835-70. doi: 10.1152/physrev.2003.83.3.835.

Reference Type: BACKGROUND

PMID: 12843410 (View on PubMed)

Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg. 2004 Nov;114(6):1502-8. doi: 10.1097/01.prs.0000138251.07040.51.

Reference Type: BACKGROUND

PMID: 15509939 (View on PubMed)

Pietramaggiori G, Scherer SS, Mathews JC, Gennaoui T, Lancerotto L, Ragno G, Valeri CR, Orgill DP. Quiescent platelets stimulate angiogenesis and diabetic wound repair. J Surg Res. 2010 May 1;160(1):169-77. doi: 10.1016/j.jss.2008.09.010. Epub 2008 Oct 10.

Reference Type: BACKGROUND

PMID: 19482315 (View on PubMed)

Kakudo N, Minakata T, Mitsui T, Kushida S, Notodihardjo FZ, Kusumoto K. Proliferation-promoting effect of platelet-rich plasma on human adipose-derived stem cells and human dermal fibroblasts. Plast Reconstr Surg. 2008 Nov;122(5):1352-1360. doi: 10.1097/PRS.0b013e3181882046.

Reference Type: BACKGROUND

PMID: 18971718 (View on PubMed)

Schultz GS, Sibbald RG, Falanga V, Ayello EA, Dowsett C, Harding K, Romanelli M, Stacey MC, Teot L, Vanscheidt W. Wound bed preparation: a systematic approach to wound management. Wound Repair Regen. 2003 Mar;11 Suppl 1:S1-28. doi: 10.1046/j.1524-475x.11.s2.1.x.

Reference Type: BACKGROUND

PMID: 12654015 (View on PubMed)

Frykberg RG, Banks J. Challenges in the Treatment of Chronic Wounds. Adv Wound Care (New Rochelle). 2015 Sep 1;4(9):560-582. doi: 10.1089/wound.2015.0635.

Reference Type: BACKGROUND

PMID: 26339534 (View on PubMed)

Knighton DR, Ciresi K, Fiegel VD, Schumerth S, Butler E, Cerra F. Stimulation of repair in chronic, nonhealing, cutaneous ulcers using platelet-derived wound healing formula. Surg Gynecol Obstet. 1990 Jan;170(1):56-60.

Reference Type: BACKGROUND

PMID: 2403699 (View on PubMed)

Other Identifiers

1

Identifier Type: -

Identifier Source: org_study_id